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Abstract Atopic dermatitis (AD) is an inflammatory skin
disease commonly affecting children and managed by
pediatricians, primary care physicians, allergists, and der-
matologists alike. For many years, the only available topical
pharmacological treatment was topical corticosteroids. This
changed in 2000–2001, when topical formulations of two
calcineurin inhibitors (tacrolimus and pimecrolimus) were
approved for short-term or chronic intermittent treatment of
AD in patients C2 years of age, in whom other treatments
have been ineffective or contraindicated. These topical cal-
cineurin inhibitors (TCIs) quickly became a popular treat-
ment option due at least in part to concerns over adverse
events associated with prolonged topical corticosteroid use,
especially in children. However, based on theoretical con-
cerns about a possible risk of lymphoma associated with TCI
use, a Boxed Warning was placed on both products in 2006.
Since then, despite an extensive body of evidence, no causal
relationship has been demonstrated between TCI use and an
increased risk of lymphoma; however, the US FDA has
concluded that a link cannot be ruled out. In fact, based on
post-marketing surveillance of spontaneous, literature, and
solicited reports, we report here that the lymphoma inci-
dence in the topical pimecrolimus-exposed population is up
to approximately 54-fold less than that seen in the general
US population. This review summarizes the mechanism of
action of TCIs, the factors that prompted the Boxed Warn-
ing, and recent TCI safety and efficacy data. Based on these
data, both topical corticosteroids and TCIs should have
defined roles in AD management, with TCIs favored for
sensitive skin areas (e.g., face) and instances where topical
corticosteroids have proven ineffective, thereby minimizing
the risk of adverse effects with both drug classes.
1 Introduction
Atopic dermatitis (AD) is an inflammatory skin disease that
predominantly affects children, with approximately 70 % of
first diagnoses made in children \5 years of age [1].
According to a US PharMetrics study, most AD sufferers are
treated by pediatricians (*30 %), dermatologists (*25 %),
or primary care physicians (*20 %) [2]. Topical cortico-
steroids have long been and remain the mainstay of AD flare
treatment; however, their use is limited by concerns about
local and systemic adverse effects with extended use [3, 4].
After their approval in 2000–2001, topical calcineurin
inhibitors (TCIs; tacrolimus 0.03 or 0.1 % and pimecrolimus
1 %) quickly became popular alternatives to topical corti-
costeroids; however, since 2006, TCI use has fallen dra-
matically after the addition of a Boxed Warning to each
product’s label about a theoretical risk of malignancy
(including lymphoma). Since that time, significant new epi-
demiologic and clinical data have become available that
challenge the validity of this warning. This article provides
an update on these data, summarizes the mechanism of
action of TCIs, discusses the factors that prompted the class-
wide warning, and provides guidance for the optimal use of
TCIs from an allergist’s perspective.
2 Atopic Dermatitis: Overview
2.1 Clinical Manifestations and Prevalence
Major clinical manifestations of AD include pruritus
(itching) and chronic or relapsing scaly lesions. Diagnostic
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criteria include evidence of itchy skin and C3 of the fol-
lowing: history of involvement of skin creases [fronts of
elbows or ankles, backs of knees, or around the neck
(including cheeks in children\10 years of age)], history of
asthma or hay fever (or, in children \4 years of age, a
history of atopic disease in a first-degree relative), history
of generally dry skin in the past year, onset before the age
of 2 years (in children C4 years of age), or visible flexural
dermatitis (including the cheeks or forehead and outer
aspects of limbs in children \4 years of age) [5].
Results of the International Study of Asthma and
Allergies in Childhood (ISAAC) demonstrated great vari-
ability in the worldwide prevalence of AD with ranges of
0.2–24.6 % for patients 13–14 years of age (n = 663,256)
and 0.9–22.5 % for patients 6–7 years of age (n =
385,853) [6]. In the US, AD is estimated to affect 10.7 %
(7.9 million) of children, and the wide range in prevalence
between regions (8.7–18.1 %) suggests that social and/or
environmental factors may play a role in disease expression
[7].
2.2 Natural History and Mechanism
The etiology of AD is very complex and not fully under-
stood. It is believed that AD is a result of interactions
between susceptibility genes and environmental factors [8].
Briefly, a genetic propensity toward a compromised epi-
dermal barrier (including gene mutations for epidermal
structural proteins such as filaggrin) increases the chances
of penetration by allergens (Fig. 1) [9]. The process of
sensitization is initiated when antigen-presenting cells,
such as Langerhans’ cells, process the antigen and present
its fragments to lymphocytes, thereby stimulating the
infiltration of helper T (Th) lymphocytes in the skin and
polarizing Th0 lymphocyte differentiation toward the Th2
subtype. These Th2 lymphocytes secrete proinflammatory
cytokines, including interleukin (IL)-3, IL-4, IL-5, and IL-
13, and stimulate humoral immune responses (acute phase)
[9]. The subsequent, chronic phase is characterized by a
shift in Th lymphocyte differentiation toward the Th1
subtype, which in turn leads to secretion of a different set
of proinflammatory cytokines (including interferon c, IL-
12, IL-11, IL-18, granulocyte-macrophage colony-stimu-
lating factor, and tumor growth factor b), as well as acti-
vation of cellular immune responses [9]. In addition,
inflamed, excoriated skin has a greater potential for colo-
nization by microorganisms such as Staphylococcus aur-
eus, which produce antigens that can further stimulate
sensitization [9].
3 Treatment Approaches
3.1 Emollients, Topical Corticosteroids,
and the Emergence of Topical Calcineurin
Inhibitors (TCIs)
There is currently no cure for AD, so disease management is
focused on trigger avoidance and alleviation of symptoms.
First-line maintenance therapy includes nonpharmacological
Fig. 1 The mechanism of atopic dermatitis and sites of action of
topical calcineurin inhibitors and topical corticosteroids. GMC-SF
granulocyte-macrophage colony-stimulating factor, IFNc interferon c,
IL interleukin, IgE immunoglobulin E, TCI topical calcineurin
inhibitor, TGF-b tumor growth factor- b, Th helper T lymphocyte
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treatment with various emollients and skin barrier repair
agents, which have been shown to improve skin appearance
and dryness and/or to reduce the need for pharmacological
treatment [1, 9]. When flares occur, anti-inflammatory agents
are used to control the inflammatory aspects of the disease.
For many years, the main pharmacological option was topical
corticosteroids; however, in December 2000, tacrolimus
ointment 0.03 % (for patients C2 years of age) and 0.1 % (for
patients [15 years of age) were approved as second-line
short-term or intermittent chronic therapy for patients
C2 years of age with moderate-to-severe AD [10]. In
December 2001, pimecrolimus cream 1 % was approved for
the same indication in patients C2 years of age with mild-to-
moderate AD [11]. Due in part to concerns about cortico-
steroid use, TCIs quickly became a popular treatment option.
Prior to the approval of tacrolimus (1997–2000), topical
corticosteroids were prescribed during 34 % of all AD-related
visits in the US; between 2001 and 2004, that percentage fell
to 25 %, and TCIs were prescribed during 23 % of visits [12].
3.2 TCIs: Mechanism of Action
Tacrolimus and pimecrolimus are macrolactams with
immunosuppressive characteristics. Both TCIs are thought
to exert their immunosuppressive effects by inhibiting the
activation of T lymphocytes, thereby decreasing the release
of the various proinflammatory cytokines discussed previ-
ously (Fig. 1) [13]. Unlike topical corticosteroids, TCIs do
not have an effect on Langerhans’ cells and do not reduce
the numbers of Th cells in healthy skin [13]. Transepi-
dermal penetration of both TCIs is lower (70- to 100-fold)
than that of topical corticosteroids, with the transepidermal
flux of pimecrolimus in cream being approximately five-
fold lower than the flux of tacrolimus in ointment [13]. Due
to these characteristics, tacrolimus and pimecrolimus have
been investigated for a number of other inflammatory skin
diseases [14] and oral and intravenous tacrolimus is indi-
cated for graft-versus-host prophylaxis [15].
3.3 TCIs: Safety and Efficacy Comparisons
with Topical Corticosteroids
The emergence of tacrolimus and pimecrolimus offered a
welcome alternative to topical corticosteroids, since the
chronic use of topical corticosteroids has been associated
with numerous adverse effects, ranging from local (skin
atrophy, rebound dermatitis, telangiectasia, striae, and
dyspigmentation) to systemic (hypothalamic–pituitary–
adrenal axis suppression, growth retardation, and Cushing’s
syndrome) [4]. The risk of specific adverse effects depends
on duration of use, corticosteroid potency, patient age, and
application site, making the rates of these adverse events
difficult to estimate [4]. It is due at least in part to the risk of
these adverse events that efficacy and safety data for topical
corticosteroids are limited. Based on the available data in
adults, TCIs appear to be as effective or more effective than
mild topical corticosteroids in controlling AD, and equally
or slightly less effective than potent topical corticosteroids
[16–21] (Table 1). Skin burning (the most frequently
reported adverse effect associated with TCI use) is more
often reported with TCIs than topical corticosteroids
(Table 1); however, it typically improves with the resolu-
tion of active AD lesions [22, 23].
4 Boxed Warning for the TCIs
4.1 Rationale
As with many drugs, the long-term safety of TCIs had not
been fully established at the time of approval, and animal
studies suggested the possibility of immune system-medi-
ated malignancy (particularly lymphomas) with systemic
exposure [24]. Furthermore, oral and intravenous tacroli-
mus administered for systemic immune suppression in
transplant recipients is associated with an increased risk of
immune-mediated malignancies, including lymphomas
[15]. Consequently, at approval, the FDA required long-
term pediatric safety registries for both agents [25, 26].
In early 2005, the FDA’s Pediatric Advisory Committee
(PAC) raised concerns about the widespread use of TCIs,
particularly off-label prescriptions to infants, which by
January 2004 had reached approximately 525,000 (14 % of
yearly prescriptions) for pimecrolimus and 69,000 (7 %)
for tacrolimus [27], and heavy direct-to-consumer adver-
tising. Based on this, the animal data (mentioned above),
and malignancy reports in the FDA’s adverse event
reporting system (AERS; 25 malignancies, 13 lymphomas
in [6.7 million potential patients), the committee recom-
mended that a Boxed Warning be added to both products
[28]. However, because the incidence of malignancy had
been low in clinical studies of either TCI ([38,000
patients, including [14,000 children), they concluded that
a causal link had not been established, but was possible and
plausible.
On January 16, 2006, the FDA accepted the PAC’s
recommendations and required that the prescribing infor-
mation for tacrolimus and pimecrolimus be amended with a
Boxed Warning. The warning states that, although a causal
relationship had not been established, ‘‘rare cases of
malignancies (e.g., skin cancer, melanoma) have been
reported in patients treated with topical calcineurin inhib-
itors [22, 23]’’. This ultimately resulted in a 79 % decrease
in TCI prescriptions [27], loss of preferred status in many
formularies, and sparked a benefit-risk debate that remains
unresolved.
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4.2 Criticism
The FDA’s decision prompted criticism by various experts
[29–32] and medical associations, including the American
College of Allergy Asthma and Immunology (ACAAI) and
the American Academy of Allergy, Asthma, and Immu-
nology (AAAAI) [33], and the American Academy of
Dermatology (AAD) [34]. The critics asserted that the
benefit-risk ratio had not been assessed appropriately,
especially in light of the impact of AD on patients and the
Table 1 Comparative efficacy and tolerability between topical calcineurin inhibitors and topical corticosteroidsa
Methodology Tolerability results Efficacy results













Meta-analysis of studies comparing
tacrolimus and pimecrolimus with
each other, topical corticosteroids, or
vehicle in patients with AD of any age
(n = 5,301) [16]
• Both TCIs are well tolerated [ [ [ \
Meta-analysis of randomized trials of
TCIs compared with topical
corticosteroids or vehicle in patients
of any age with AD (n = 6,687) [17]
• Skin burning is more
frequent with both TCIs than
topical corticosteroids
• Neither TCI is associated
with risk of skin infection
compared with vehicle or
topical corticosteroids
[ [ = [ b \
Meta-analysis of randomized controlled
trials comparing tacrolimus with
pimecrolimus, topical corticosteroids,
or vehicle in children with AD
(n = 712 tacrolimus-treated) [18]
• Tacrolimus is similar in
tolerability to vehicle and
pimecrolimus, but greater in
tolerability than 1 % HCT
• Burning and pruritus are
among the most frequent
adverse events
[ [
Systematic review of randomized
controlled trials of TCIs compared
with topical corticosteroids or vehicle
in patients of any age with AD
(n = 7,378) [19]
[ [ = [ = \
Meta-analysis of randomized controlled
trials of TCIs compared with topical
corticosteroids or vehicle in children
with AD (n = 4,234) [20]
• Both TCIs have tolerability
profiles similar to vehicle
[ [c [d
Meta-analysis of randomized controlled
trials of tacrolimus compared with
topical corticosteroids in children
(n = 2,328) and adults (n = 2,849)
with AD [21]
• Tacrolimus and topical
corticosteroids are similar in
tolerability, with the
exception of skin burning
[ [ =
AD atopic dermatitis, CS corticosteroid, HCT hydrocortisone, TCI topical calcineurin inhibitor
[ indicates more effective, \ indicates less effective, = indicates as effective
a As identified using PubMed searches for peer-reviewed systematic reviews or meta-analyses comparing the efficacy and/or tolerability of
tacrolimus and/or pimecrolimus with topical corticosteroids in patients with atopic eczema [ie, topical and (tacrolimus or pimecrolimus or
calcineurin) and (corticosteroids or halobetasol or diflorasone or desoximetasone or clocortolone or triamcinolone or betamethasone or
hydrocortisone or clobetasol or fluocinonide or fluocinolone or mometasone or fluticasone or alclometasone or prednicarbate or desonide) and
(eczema or ‘‘atopic dermatitis’’), limited to systematic review/meta-analysis publication type, human species, and English language]
b Comparisons not available or limited
c Applied to face, neck, and intertriginous areas
d Applied to trunk and limbs
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risk of significant adverse effects with topical corticoste-
roids [30–32]. They contended that the results of the ani-
mal studies, which were conducted with an aim of
determining dosages that produced toxicity, could not be
generalized to humans because of differences in adminis-
tration and/or formulation, inherent biological differences
between humans and animals, and large differences in
systemic exposure (26- to 340-fold greater than the maxi-
mum levels observed in humans) [29, 33].
In addition, they pointed out that the incidence of
lymphoma in TCI-treated patients was no greater than
that seen in the general population. In fact, in the pime-
crolimus post-marketing surveillance (including solic-
ited, spontaneous, and literature reports), the incidence of
any lymphoma is 0.41/100,000 patient-years of exposure
[2], whereas the age-adjusted incidence of Hodgkin’s and
non-Hodgkin’s lymphoma combined in the general pop-
ulation is 22.0/100,000 patient-years [35]. That is, there
is up to approximately a 54-fold higher incidence of
lymphoma in the general population compared with those
exposed to topical pimecrolimus; however, such calcu-
lations based on post-marketing reports are subject to
under-reporting. Even if only 5 % of actual lymphoma
cases are reported, the adjusted incidence of lymphoma
among TCI users would still be nearly threefold lower
than the background incidence in the general population.
Furthermore, experts agree that misdiagnosis due to
overlapping presentation with cutaneous T cell lym-
phoma (CTCL) and an association between AD itself and
cancer risk complicate the analysis [36].
5 New Evidence, Incomplete Conclusions
A comprehensive review of TCI safety was released by the
FDA in September 2010 [37], with an addendum released
in May 2011 [38]. The 2010 review summarized data from
five peer-reviewed studies [39–43] and a study that has so
far been published only in abstract form [44, 45]; these six
studies evaluated a combined population of [6 million
patients [37] (Table 2).
Despite this large volume of epidemiological data,
the FDA concluded that there still may be ‘‘a possibility
of an association’’ between tacrolimus (pimecrolimus is
not mentioned) and an increased risk of lymphoma but,
‘‘causality is difficult to determine in light of potential
study biases’’ and ‘‘applicability of the reported results
specifically to the pediatric population and the long-
term safety profile of [tacrolimus] remain in question
[38]’’.
As of May 2011, a total of 72 cases of malignancy in
TCI-treated children had been reported to the FDA (17
before the Boxed Warning and 55 after): 25 lymphomas, 25
leukemias, 8 skin malignancies, and 14 other types of
cancer [46]. The FDA reviewers concluded that these cases
‘‘support the previously observed potential signal for
malignancies reported with TCI use’’; however, they also
state that the available information is not sufficient to
determine causality.
6 An Allergist’s Perspective: Optimizing Therapy
with TCIs
6.1 Recommendations
As noted above, the total number of TCI prescriptions has
fallen precipitously since 2004 [27]. This suggests that a
relatively large number of patients have been denied the
benefits of TCI therapy on the grounds of a speculative
assessment of risk. Also implied is an increase in topical
corticosteroid use, along with all its associated risks, espe-
cially when used in sensitive areas such as the face and
around the eyes [12]. While care should be used in pre-
scribing TCIs, available evidence suggests that the concerns
of the PAC have not been borne out during the 7 years since
the Boxed Warning was initiated. Although topical cortico-
steroids should remain first-line therapy for AD flares, there
are a number of situations in which TCIs should be consid-
ered. Currently, TCIs are indicated for use in patients who do
not respond to topical corticosteroid treatment or in whom
topical corticosteroid use is contraindicated [22, 23]. In
addition, for patients with particularly severe AD who
require long-term treatment, chronic intermittent and proac-
tive use of TCIs may be more appropriate than topical cor-
ticosteroids, given the limited data available for long-term
use of topical corticosteroids [47]. Likewise, in sensitive skin
areas such as the face, neck, or genitals, corticosteroid use
may not be suitable due to a greater risk of telangiectasia and
higher systemic exposure resulting from a thinner epidermal
barrier in those areas [3, 4]. Furthermore, corticosteroid use
in the periorbital region can lead to corticosteroid-induced
vasoconstriction and glaucoma [4]. These concerns are par-
ticularly relevant in the case of children, who are more likely
to have AD, more likely to have AD in sensitive-skin areas,
and have a higher body surface/volume ratio that enhances
the risk of systemic exposure to corticosteroids. In rare cases,
systemic exposure may lead to hypothalamic–pituitary–
adrenal axis suppression and growth retardation [4]. In some
instances, it may also be reasonable to consider using TCIs in
combination with topical corticosteroids; for example, the
use of a topical corticosteroid of appropriate potency on the
body (i.e., below the neck) and a TCI on the face, or in areas
where topical corticosteroids have been ineffective. With
such an approach, the total exposure to both TCIs and topical
corticosteroids would be reduced, thereby decreasing the risk
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of adverse effects associated with either drug class. Fur-
thermore, counselling patients to limit or avoid sun exposure
will mitigate risk of cutaneous malignancy, as recommended
in the package insert [23].
6.2 Challenges Associated with Prescribing TCIs
Due to the Boxed Warning, prescribing TCIs has become
difficult due to a number of factors, not least of which is
barriers to patient access and reimbursement put in place by
insurers and other payers. Even when they are prescribed as
indicated, the Boxed Warning often dissuades patients, and
even some doctors (especially those less familiar with the
history of the debate), from using them. However, it is our
responsibility, as physicians, to ensure that patients receive
the best possible care, particularly when first-line therapies
do not provide sufficient relief, or if there are relevant safety
concerns. We physicians must also sufficiently explain the
benefits and risks of the therapies we prescribe, which, in the
case of TCIs, may require longer consultation times. There is
currently no standard method for communicating the risks
and benefits of TCIs. A consensus document, directed toward
Table 2 Epidemiological studies of topical calcineurin inhibitor use and malignancy risk (including lymphoma)a
Database Design and population Results
Survey of dermatology
outpatients with AD
Nested case-controlled cohort of 3,535
patients [30 years of age
• No association between TCI use and increased risk of non-
melanoma skin cancer [39]
US PharMetrics Health Claims
Database
Nested case-controlled cohort of 293,253
patients of any age with AD
• No increased risk of lymphoma in TCI-treated patients
compared with non-use [40]
• Severity of AD was the main factor associated with
increased risk of lymphoma [40]
• 9 of 81 patients \20 years of age who developed
lymphoma had TCI exposure—4 to tacrolimus, 4 to
pimecrolimus, and 1 to both [38]
US PharMetrics Health Claims
Database (extension of
previous)
Nested case-controlled cohort of 625,915
patients of any age with AD
• No increased risk of overall lymphoma in TCI- or topical
corticosteroid-treated patients compared with non-use;
results were similar for patients\20 years of age [38, 44,
45]
• Possible significantly higher risk of non-Hodgkin’s and
T-cell lymphoma in patients treated with tacrolimus (but




Nested case-control study of 3,500,194
patients\80 years of age who used TCIs or
topical corticosteroids
• No association between TCI use and lymphoma riskb [41]
• Significant correlation between topical corticosteroid use
and risk of lymphoma, especially skin lymphoma [41]
Kaiser Permanente California
Databases
Cohort of 953,064 patients of any age with
AD
• No association between TCI use and risk of malignancy
[42]
• Possible association between risk of CTCL and exposure to
tacrolimus (but not pimecrolimus) [42]
• 1 of 12 patients with a confirmed diagnosis of lymphoma
was B20 years of age (this patient was exposed to both
TCIs) [38]
United Health Care Health
Claims Database
Propensity-matched cohort of 1,200,645
patients of any age including:
• Patients with AD who initiated
pimecrolimus, tacrolimus, or medium/
potent topical corticosteroids
• Patients with AD who did not initiate AD
treatment
• Controls without AD who had no TCI/
topical corticosteroid exposure
• No increased risk of lymphoma (including CTCL) with
initiation of pimecrolimus compared with initiation of
tacrolimus or medium/potent topical corticosteroids [43]
• Of patients B5 years of age:
s None had a diagnosis of lymphoma during the 6-month
period following the index date [38]
s Two had a diagnosis of lymphoma overall (one patient
with CTCL and one with ‘‘any lymphoma’’; both were
exposed to tacrolimus) [38]
AD atopic dermatitis, CTCL cutaneous T-cell lymphoma, TCI topical calcineurin inhibitor
a As identified in the FDA’s calcineurin inhibitor pediatric literature review [37, 38]
b The low number of TCI-treated patients made the determination of a link impossible
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patients and caregivers, that places the risks into context
would be useful. Unfortunately, no such document exists.
Until such a document becomes available, physicians should
stay informed of the issues surrounding TCI use so that they
can adequately answer questions and discuss potential
problems with insurance coverage and/or preauthorization
prior to prescribing. It is also important to work with phar-
macists to consistently communicate the risks and benefits of
pharmacotherapies for AD.
Due to the relatively low incidence of malignancy
(including lymphoma) in patients taking TCIs, it may never
be possible to completely exclude the possibility of a causal
relationship between TCI use and cancer, regardless of the
number of patients who are monitored. However, some
patients and caregivers may be comforted by the fact that both
AAD and AAAAI/ACAAI have challenged the inclusion of
the Boxed Warning. The AAD website states that:
The medicines that dermatologists prescribe are safe
when used as directed…The [AAD] believes that
these Warnings confuse and unnecessarily worry
people. Studies prove that with proper use, topical
pimecrolimus and tacrolimus are not dangerous.
When applied to the skin, virtually none of the med-
icine gets inside the body. When used properly, the
medicines reduce the debilitating effect of [AD] and
allow millions of people to live normal lives [48].
7 Conclusions
In the 7 years since the Boxed Warning was implemented,
no conclusive proof has emerged that links TCI use to
malignancy risk, despite extensive monitoring and analy-
sis. However, a theoretical possibility remains, and so does
the Boxed Warning. In this context, it may be appropriate
to challenge the treatment paradigm of using TCIs only
after failure of topical corticosteroids. Not adopting such a
treatment strategy may deprive many patients, especially
children, of effective AD management, while putting them
at risk for corticosteroid-associated adverse effects. That is
why the author recommends (and currently prescribes,
when appropriate) TCIs for sensitive skin areas (‘‘above the
neck’’) and topical corticosteroids for the rest of the body
(‘‘below the neck’’). In the meantime, we as physicians
must remain informed about this debate and be ready to
explain the benefit-risk ratios of both TCIs and topical
corticosteroids to our patients and their caregivers. Con-
tinued monitoring and future studies may shed more light
on this question.
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